Sequence intelligence
Therapies are evaluated as ordered evolutionary interventions rather than independent drug scores.
Tumor evolution intelligence · evidence gated
Engineer tumor evolution
before resistance wins.
GENESIS Oncology is a treatment-sequence intelligence platform designed to reason about what a therapy selects for next — linking tumor state, intervention, lineage response and replacement escape in one controlled decision architecture.
FocusEvolutionary sequencing
ArchitectureState × Action × Lineage
ValidationOutcome-embargoed
Releasev0.6.9 · O-1.11F
A different oncology question
Not “which drug works now?”
“What does this treatment make possible next?”
GENESIS treats treatment as an evolutionary intervention. The objective is to understand how one action reshapes the tumor population and changes the risk landscape for the next action.
Latent reservoir reasoning
The architecture is built to track small or hidden states that can become dominant after selection pressure.
Replacement Escape
GENESIS explicitly models the risk that suppressing one population creates room for another resistant population to replace it.
Evidence-gated release
A sophisticated model is not allowed to influence a decision merely because it fits data. It must clear prespecified transfer and utility gates.
What GENESIS has already accomplished
From concept to a reproducible decision system.
These are research-validation milestones, not clinical efficacy claims. They show that the platform has moved beyond a conceptual framework into a tested, auditable and increasingly blinded engineering system.
One of the platform’s core strengths is methodological: when a dataset cannot establish transferable decision utility, GENESIS does not manufacture a positive result by repeatedly tuning against the same outcomes. Outcomes are embargoed and the next test moves to fresh evidence.
Mathematical rigor & biological constraints
GENESIS does not merely fit tumor data.
It tests what the data can physically identify.
During development, GENESIS exposed several constraints that any defensible tumor-evolution model must respect. These findings shape the platform’s measurement model, validation gates and abstention logic.
Correlation ≠ quantitative identity
Extracellular DNA can create false biological confidence.
In the analyzed paired cellular/extracellular DNA setting, Pearson correlation reached 0.7904 while concordance correlation was only 0.0183. GENESIS therefore does not treat a strong correlation as sufficient evidence that extracellular DNA quantitatively represents the viable tumor reservoir.
Implication: shedding/death signals and viable-state inference are modeled as distinct observation processes.
Gauge non-identifiability
Relative abundance cannot uniquely reveal absolute tumor dynamics.
GENESIS derived an algebraic invariance under which distinct latent proliferation/loss states produce observationally equivalent relative measurements, with numerical equivalence to approximately 1.11 × 10−16.
B · pV · C · qS · κ
The platform therefore treats absolute burden and additional observation operators — including the five-component breaker structure above — as necessary information for resolving the degeneracy rather than forcing a unique answer from relative data alone.
Lineage-dependent observation bias
Rare lineages can be observed very differently across modalities.
GENESIS found asymmetric rare-lineage enrichment reaching approximately 4.686× in the analyzed scRNA-linked setting. That makes a single universal shedding/observation constant unsafe as a default assumption.
Implication: observation bias may depend on lineage, state and treatment history and must be estimated or bounded rather than assumed away.
Active abstention
Refusing an unsupported decision is part of the control architecture.
GENESIS evaluates incremental decision utility and counterfactual regret against simpler controls. When a treatment sequence cannot demonstrate prespecified utility lift, the system withholds the ranking instead of converting uncertainty into an unsafe command.
Implication: abstention is an engineered safety primitive for avoiding unsupported Replacement Escape decisions, not a software failure state.
Correlation is not biological identity.
Relative abundance is not absolute tumor dynamics.
A model that cannot justify an action should be allowed to abstain.
Platform architecture
One evidence graph from biology to action.
The long-term target is an oncology control layer that can connect measured tumor state to treatment-specific evolutionary consequences and select the next action only when evidence supports it.
01Tumor stateObserved + latent state representation
→02Treatment actionAction-specific perturbation
→03Lineage consequenceWhat survives, expands or disappears
→04Escape landscapeReplacement and resistance risk
→05Next decisionAct, abstain or acquire evidence
Oncology R&D
Treatment-sequence programs
Compare ordered interventions where the first treatment changes the state on which the second treatment must act.
Resistance research
Escape-mechanism stratification
Separate present response from future evolutionary vulnerability and identify what new measurements are decision-changing.
Partner validation
Blind evidence programs
Freeze predictions before outcome reveal and create an auditable boundary between model development and independent evaluation.
Validation frontier
The next gate is deliberately difficult.
The Replacement Escape Ranker is currently withheld pending a fresh, outcome-embargoed independent matrix under the O-1.11D validation contract. Release requires prespecified evidence of transferable, action-specific decision utility.
This boundary is a validation status, not a clinical claim. GENESIS Oncology is a research platform and is not a medical device.
Strategic collaboration
Bring GENESIS a decision that can fail.
We are seeking high-quality oncology partners for blinded, preclinical validation of treatment-sequence and replacement-escape intelligence.